Braun Stacey Associates Inc. Has $25.40 Million Stock Holdings in Ascendis Pharma A/S $ASND

Braun Stacey Associates Inc. boosted its position in Ascendis Pharma A/S (NASDAQ:ASND) by 26.8% in the 4th quarter, HoldingsChannel reports. The firm owned 119,095 shares of the biotechnology company’s stock after acquiring an additional 25,148 shares during the period. Braun Stacey Associates Inc.’s holdings in Ascendis Pharma A/S were worth $25,396,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Rhumbline Advisers increased its position in Ascendis Pharma A/S by 4.0% during the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after buying an additional 55 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Ascendis Pharma A/S by 1.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,081 shares of the biotechnology company’s stock valued at $1,209,000 after buying an additional 58 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Ascendis Pharma A/S by 0.6% in the second quarter. China Universal Asset Management Co. Ltd. now owns 12,186 shares of the biotechnology company’s stock valued at $2,103,000 after buying an additional 73 shares during the last quarter. Jones Financial Companies Lllp boosted its stake in shares of Ascendis Pharma A/S by 57.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 83 shares during the period. Finally, GAMMA Investing LLC boosted its stake in shares of Ascendis Pharma A/S by 15.2% during the 3rd quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 97 shares during the period.

Analyst Ratings Changes

A number of research firms recently weighed in on ASND. Royal Bank Of Canada increased their price target on Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a research note on Monday, March 2nd. Wolfe Research reiterated an “outperform” rating and issued a $260.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Oppenheimer increased their price objective on shares of Ascendis Pharma A/S from $246.00 to $262.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Wedbush raised their target price on shares of Ascendis Pharma A/S from $240.00 to $273.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Finally, Stifel Nicolaus set a $332.00 target price on shares of Ascendis Pharma A/S in a report on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $289.89.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $229.25 on Friday. The firm has a market cap of $14.29 billion, a P/E ratio of -52.10 and a beta of 0.49. The business’s 50 day moving average is $227.16 and its 200-day moving average is $213.91. Ascendis Pharma A/S has a 1-year low of $124.06 and a 1-year high of $248.60.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Thursday, February 12th. The biotechnology company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.58). The business had revenue of $290.38 million during the quarter, compared to analysts’ expectations of $285.35 million. Analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.